8-K
filed June 8, 2023, 7:59 PM ET
ticker EVH
CIK 0001628908
other material
confidence high
sentiment neutral
materiality 0.15
Evolent Health shareholders approve all proposals at 2023 annual meeting
Evolent Health, Inc.
- All nine director nominees elected with large majorities; no opponent received >8% against.
- Deloitte & Touche ratified as auditor for FY 2023: 105,998,310 for, 17,515 against.
- Advisory say-on-pay for 2022 NEO compensation approved: 98,899,814 for, 1,875,305 against.
- Amendment to 2015 Omnibus Incentive Compensation Plan approved: 96,632,166 for, 4,123,883 against.
- Meeting held June 8, 2023; broker non-votes of 5,271,272 on all director and compensation proposals.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Evolent Health, Inc. shareholders approved Advisory approval of the compensation of named executive officers for 2022 at the 2023-06-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 3 The Company’s stockholders approved the compensation of our named executive officers for 2022 on an advisory basis, as set forth below: For Against Abstentions Broker Non-Votes 98,899,814 1,875,305 51,305 5,271,272
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Evolent Health, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 2 The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023, as set forth below: For Against Abstentions 105,998,310 17,515 81,871
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Evolent Health, Inc. shareholders approved Amendment to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan at the 2023-06-08 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 4 The Company’s stockholders approved the amendment to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, as set forth below: For Against Abstentions Broker Non-Votes 96,632,166 4,123,883 70,375 5,271,272
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Evolent Health, Inc. shareholders approved Election of nine director nominees at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 1 The Company’s stockholders elected each of the nine director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company’s 2024 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below: For Against Abstentions Broker Non-Votes Craig Barbarosh 92,628,578 8,130,483 67,363 5,271,272 Seth Blackley 100,249,455 512,031 64,938 5,271,272 M. Bridget Duffy, MD 98,022,157 2,736,856 67,411 5,271,272 Peter Grua 100,073,314 685,697 67,413 5,271,272 Diane Holder 92,977,179 7,781,884 67,361 5,271,272 Richard Jelinek 100,401,040 357,986 67,398 5,271,272 Kim Keck 98,212,241 2,546,772 67,411 5,271,272 Cheryl Scott 96,462,765 4,296,263 67,396 5,271,272 Tunde Sotunde, MD 100,245,662 513,433 67,329 5,271,272
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.